In Part 3 of this three-part series, panelists discuss the applicability in the US of a value-based agreement for a TKI therapy for renal cell carcinoma in the UK.
The discussion took place during the American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2019; Chicago, IL) and was moderated by Omar Ali, BSc(Honors)Pharm, DipClinPharm, MRPharmS, ACPP, head of payers, Verpora (United Kingdom).
- Andrew Hertler, MD, FACP, chief medical officer, New Century Health;
- Dan Wygal, executive director of contract and channel strategy, AstraZeneca; and
- Daniel Vaena, MD, medical oncologist, West Cancer Center.